Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Barry Marshall awarded Nobel prize for Helicobacter pylori discovery

Barry Marshall and Robin Warren's work produced one of the most radical and important changes in the last 50 years in the perception of a medical condition, and subsequently peptic ulcers are often no longer a disabling problem.

News image

fiogf49gjkf04

Barry Marshall and colleague Robin Warren have been awarded the Nobel prize for Medicine.

Barry Marshall is a member of the global faculty at GastroHep.com.

The research team discovered that peptic ulcer are usually caused by a bacterial infection.

The researchers will equally share the prize, which brings an award of approximately $1.3-million.

Sweden's Karolinska Institute will present the prize in December.

The researchers showed the bacterium H pylori plays a key role in the development of both gastric and duodenal ulcers, as well as a pivotal role in the development of gastric cancer.

Barry Marshall completed his undergraduate medical degree at the University of Western Australia in 1974, and an internship at Queen Elizabeth II Medical Centre.

Barry Marshall met Robin Warren during internal medicine fellowship training at Royal Perth Hospital in 1981.

Profesor Warren paved the way for the breakthrough when he discovered that small curved bacteria colonised the lower part of the stomach in about 50% of patients from which biopsies had been taken.

He also made the crucial observation that signs of inflammation were always present in the stomach lining close to where the bacteria were seen.

Barry Marshall became interested in the findings and together the researchers initiated a study of biopsies from 100 patients.

Barry Marshall proved H. pylori caused gastric inflammation by deliberately infecting himself with the bacterium
BBC News

Together, the pair studied the presence of spiral bacteria in association with gastritis.

After several attempts, Dr Marshall succeeded in cultivating a hitherto unknown bacterial species - H pylori - from several of these biopsies.

Together the researchers found that the organism was present in almost all patients with gastric inflammation, duodenal ulcer or gastric ulcer.

Even though stomach ulcers could be healed by inhibiting gastric acid secretion, they frequently relapsed.

The research team noted that the peptic ulcers tended to recur because bacteria and chronic inflammation of the stomach remained.

Barry Marshall and showed patients could only be cured when H pylori was eradicated from the stomach.

Dr Marshall proved that H pylori caused gastic inflammation by deliberately infecting himself with the bacterium.

The work produced one of the most radical and important changes in the last 50 years in the perception of a medical condition.

The Nobel citation praises the doctors for their tenacity, and willingness to challenge prevailing dogmas.

"By using technologies generally available they made an irrefutable case that the bacterium H pylori is causing disease.

"By culturing the bacteria they made them amenable to scientific study."

Lord May of Oxford, President of the Royal Society, commented, "The work by Barry Marshall and Robin Warren produced one of the most radical and important changes in the last 50 years in the perception of a medical condition.”

"Their results led to the recognition that gastric disorders are infectious diseases, and overturned the previous view that they were physiological illnesses."

On becoming a researcher, Dr Marshall commented, “When I was in medical school I was given the impression that everything had already been discovered in medicine.”

“So I never thought that medical research would be interesting, but as I did my internship ... I realised there were a lot of people who had things wrong with them that you couldn't do anything about particularly."

In 1982, when H pylori was discovered by the researchers, stress and lifestyle were considered the major causes of stomach and intestinal ulcers.

It is now firmly established that the bacterium causes more than 90% of duodenal ulcers and up to 80% of gastric ulcers.

As a result of the researchers' work, these ulcers are often no longer a long-term, frequently disabling problem and can be cured with a short-term course of antibiotics taken with a gastric acid anti-secretory drug.

BBC 2005: 3 October, 10:07 GMT
04 October 2005

Go to top of page Email this page Email this page to a colleague

 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 21 February 2018 
Management of hemorrhoids in the USA
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 20 February 2018 
Complications and surveillance colonoscopies
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us